TREK-1: The Leak Channel Researchers Push in Both Directions

TREK-1, encoded by KCNK2, belongs to the two-pore-domain potassium channel family — the K2P channels. Unlike voltage-gated potassium channels, which open in response to depolarization, K2P channels conduct a background or leak current across a wide range of membrane potentials.

That leak is what sets the resting membrane potential. By permitting a steady hyperpolarizing K⁺ efflux, TREK-1 activity holds neurons further from firing threshold, which the literature associates with reduced hyperexcitability and limited intracellular Ca²⁺ overload during ischemic insults.

Expression is concentrated where that matters: cortex, hippocampus, and striatum in the brain, and vascular smooth muscle cells in the periphery. The peripheral expression is why TREK-1 appears in neurovascular coupling and vascular tone research as well as in purely neuronal work.

TREK-1 is described in the literature as a polymodal molecular sensor. Rather than responding to a single stimulus, its open probability integrates several physical and chemical inputs at once.

Most ion-channel targets are pursued in one direction. TREK-1 is unusual because both directions have active research programs, aimed at different endpoints.

Blocking the channel removes the hyperpolarizing brake. In rodent models this is reported to mimic the KCNK2 knock-out phenotype — upregulated brain-derived neurotrophic factor (BDNF), increased hippocampal neurogenesis, and antidepressant-like behavioural readouts.

Opening the channel does the opposite at the membrane: more K⁺ efflux, deeper hyperpolarization, and a neuron that is harder to drive into excitotoxic depolarization. That is the ischemia and epilepsy line of research.

The two are not contradictory so much as differently scoped. One targets plasticity and trophic signaling over days; the other targets survival during an acute metabolic insult. Reading either literature as a claim about the other is the most common way to misread this target.

Spadin is a naturally occurring 17-amino-acid peptide derived from the propeptide of the sorting protein-related receptor SORLA. PE-22-28 is a shortened, stabilized synthetic analog developed for higher affinity and better in vivo stability, reported to block TREK-1 with an IC₅₀ near 0.12 nM.

The science: pharmacological blockade removes the leak conductance that holds the resting potential down. In rodent models this is characterized as reproducing the KCNK2 knock-out phenotype without the developmental confounds of a genetic model.

Reported effects: rapid upregulation of BDNF, enhanced hippocampal neurogenesis, and neuroprotective readouts in post-stroke recovery models.

BL-1249 is a non-steroidal anti-inflammatory derivative repurposed in the literature as a direct TREK-1 opener. It stabilizes the channel's open state, increasing potassium efflux rather than merely permitting it.

The science: the resulting hyperpolarization moves the membrane further from threshold, which is described as making cells resistant to excitotoxic depolarization — the glutamate-driven cascade that converts an ischemic insult into cell death.

Research scope: models of epilepsy, pain signaling, and cerebral ischemia, generally as a tool compound for asking what happens when the leak is amplified.

Not stocked in the Revitalized catalog. It appears here because the antagonist literature is hard to interpret without the opener side for contrast.

Alpha-linolenic acid (ALA) and related polyunsaturated fatty acids are endogenous TREK-1 modulators. They intercalate into the membrane, alter its physical tension, and open the channel allosterically — the same mechanical pathway that stretch acts through.

The science: this is the channel's native regulatory input rather than a pharmacological intervention, which is part of why it draws interest. The lipid environment is already tuning TREK-1 continuously.

Reported effects: neuroprotection in rodent models of transient global ischemia, attributed to dampened inflammatory cascades alongside reduced hyperexcitability.

Not stocked as a research compound.

Isoflurane and sevoflurane directly activate TREK-1, and this is understood to contribute meaningfully to their central depressant profile — part of how these agents work is a background potassium conductance being turned up.

Research scope: perioperative neuroprotection, asking whether channel activation during surgery blunts ischemic brain injury.

These are regulated clinical anesthetics administered by licensed practitioners. They are named here only because they are a major line of TREK-1 evidence. They are not research compounds, they are not available from us, and nothing in this reference should be read as suggesting otherwise.

PE-22-28 is available as a research compound. BL-1249, alpha-linolenic acid, and the volatile anesthetics are referenced for mechanistic context only and are not part of the catalog.